634 reports of this reaction
3.3% of all INSULIN GLULISINE reports
#3 most reported adverse reaction
HYPERGLYCAEMIA is the #3 most commonly reported adverse reaction for INSULIN GLULISINE, manufactured by sanofi-aventis U.S. LLC. There are 634 FDA adverse event reports linking INSULIN GLULISINE to HYPERGLYCAEMIA. This represents approximately 3.3% of all 19,263 adverse event reports for this drug.
Patients taking INSULIN GLULISINE who experience hyperglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERGLYCAEMIA is moderately reported among INSULIN GLULISINE users, representing a notable but not dominant share of adverse events.
In addition to hyperglycaemia, the following adverse reactions have been reported for INSULIN GLULISINE:
The following drugs have also been linked to hyperglycaemia in FDA adverse event reports:
HYPERGLYCAEMIA has been reported as an adverse event in 634 FDA reports for INSULIN GLULISINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERGLYCAEMIA accounts for approximately 3.3% of all adverse event reports for INSULIN GLULISINE, making it one of the most commonly reported side effect.
If you experience hyperglycaemia while taking INSULIN GLULISINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.